CAS: 10-33-3 - (1beta,6beta,7alpha,8alpha,13alpha,14R)-1,6,7,14-tetrahydroxy-15-oxo-7,20-epoxykaur-16-en-18-yl acetate

Formule : C₂₂H₃₀O₈

InChI : InChI=1/C22H30O8/c1-10-12-4-5-13-20-9-30-22(28,21(13,16(10)25)17(12)26)18(27)15(20)19(3,7-6-14(20)24)8-29-11(2)23/h12-15,17-18,24,26-28H,1,4-9H2,2-3H3/t12-,13?,14+,15?,17+,18-,19-,20?,21-,22-/m0/s1

Tiotropium impurity mixture CRS

CAS : 10-33-3

Moxifloxacin for system suitability CRS

CAS : 10-33-3

Nicotinic acid impurity mixture CRS

CAS : 10-33-3

Moxifloxacin for peak identification A CRS

CAS : 10-33-3

Mitoxantrone impurity A CRS

CAS : 10-33-3

Nicorandil impurity A CRS

CAS : 10-33-3

Fluorouracil impurity mixture CRS

CAS : 10-33-3

Enalapril impurity G CRS

CAS : 10-33-3

Moxifloxacin for peak identification B CRS

CAS : 10-33-3

Lacosamide impurity F CRS

CAS : 10-33-3

Ketotifen for peak identification CRS

CAS : 10-33-3

Salbutamol impurity J CRS

CAS : 10-33-3

Doxapram impurity B CRS

CAS : 10-33-3

Salbutamol impurity F CRS

CAS : 10-33-3

Ketotifen impurity G CRS

CAS : 10-33-3

Nizatidine impurity F CRS

CAS : 10-33-3

Levofloxacin for system suitability CRS

CAS : 10-33-3

Lacosamide impurity D CRS

CAS : 10-33-3

Salbutamol impurity I CRS

CAS : 10-33-3

Atomoxetine impurity D CRS

CAS : 10-33-3

Azelastine impurity D CRS

CAS : 10-33-3

Pregabalin impurity B CRS

CAS : 10-33-3

Guaifenesin for peak identification CRS

CAS : 10-33-3

Ondansetron impurity G CRS

CAS : 10-33-3

Orphenadrine impurity E CRS

CAS : 10-33-3